Clinical Trials

20 enrolled

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Hodgkin Disease, Recurrence

NCT05355051 2026-04-15

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

24 enrolled

Hodgkin Disease

NCT06863402 2026-03-24

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02332668 2026-03-16

MK-3475-051

370 enrolled

Lymphoma, Melanoma

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Phase 1 Recruiting

15 enrolled

Lymphoma

NCT04752826 2026-02-18

MK-3475-D20

DermatologicGynecologicLymphoid

176 enrolled

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT06484920 2026-02-10

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

24 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

84 enrolled

Hodgkin Disease

NCT03829254 2026-01-12

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

135 enrolled

Lymphoma, Melanoma

NCT05956041 2026-01-07

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

23 enrolled

Lymphoma, T-Cell, Cutaneous

NCT07283822 2025-12-16

Amping up With PemJAK

53 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT06812858 2025-08-19

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

83 enrolled

Hodgkin Disease

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Hodgkin Disease

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

32 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Phase EARLY_PHASE1 Recruiting

Hodgkin Disease, Recurrence

NCT04541108 2024-04-18

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

15 enrolled

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT06180733 2023-12-22

PAM-II

12 enrolled

GynecologicLymphoid

Lymphoma, Follicular, Uterine Neoplasms, Endometrial Neoplasms

NCT04920617 2023-04-07

VITALIZE

102 enrolled